中国伤残医学
中國傷殘醫學
중국상잔의학
CHINESE JOURNAL OF TRAUMA AND DISABILITY MEDICINE
2013年
7期
48-49
,共2页
氟喹诺酮类药物%莫西沙星%左氧氟沙星%耐多药结核病%化疗方案%疗效
氟喹諾酮類藥物%莫西沙星%左氧氟沙星%耐多藥結覈病%化療方案%療效
불규낙동류약물%막서사성%좌양불사성%내다약결핵병%화료방안%료효
Fluoro-quinolon%Moxifloxacin%Levofloxacin%Multidrug-resistant tuberculosis(MDR-TB)%Chemotherapy%Efficacy
目的：观察和评价氟喹诺酮类药物结合一、二线抗TB药物治疗耐多药结核病（ MDR-TB）临床有效性及安全性。方法：将156例MDR-TB患者随机分为2组，其中观察组采用6MfxZPtoKmPAS/18MfxZPtoPAS（莫西沙星＋吡嗪酰胺＋丙硫异烟胺＋卡那霉素＋对氨基水杨酸）化疗方案；对照组采用6LfxZPtoKmPAS/18LfxZPtoPAS（左氧氟沙星＋吡嗪酰胺＋丙硫异烟胺＋卡那霉素＋对氨基水杨酸）化疗方案。疗程24个月。结果：2组疗程完成后，观察组79例患者显效62例，总有效率为96．20％，对照组77例患者显效49例，总有效率为84．42％，2组临床疗效比较差异有显著性（ P＜0．01），而观察组患者3个月、12个月痰菌阴转率分别为55．69％，73．42％，24个月疗程结束时累计有68例患者痰菌阴转，阴转率为86．08％，均高于对照组，且差异显著有统计学意义（P＜0．05），观察组不良反应发生率为16．46％（13/79）；对照组为15．58％（12/77），2组比较差异无统计学意义（P＞0．05）。结论：氟喹诺酮类药物结合一、二线抗TB药物治疗耐多药结核病（MDR-TB）临床无交叉耐药性，疗效显著，且有较高安全性。
目的：觀察和評價氟喹諾酮類藥物結閤一、二線抗TB藥物治療耐多藥結覈病（ MDR-TB）臨床有效性及安全性。方法：將156例MDR-TB患者隨機分為2組，其中觀察組採用6MfxZPtoKmPAS/18MfxZPtoPAS（莫西沙星＋吡嗪酰胺＋丙硫異煙胺＋卡那黴素＋對氨基水楊痠）化療方案；對照組採用6LfxZPtoKmPAS/18LfxZPtoPAS（左氧氟沙星＋吡嗪酰胺＋丙硫異煙胺＋卡那黴素＋對氨基水楊痠）化療方案。療程24箇月。結果：2組療程完成後，觀察組79例患者顯效62例，總有效率為96．20％，對照組77例患者顯效49例，總有效率為84．42％，2組臨床療效比較差異有顯著性（ P＜0．01），而觀察組患者3箇月、12箇月痰菌陰轉率分彆為55．69％，73．42％，24箇月療程結束時纍計有68例患者痰菌陰轉，陰轉率為86．08％，均高于對照組，且差異顯著有統計學意義（P＜0．05），觀察組不良反應髮生率為16．46％（13/79）；對照組為15．58％（12/77），2組比較差異無統計學意義（P＞0．05）。結論：氟喹諾酮類藥物結閤一、二線抗TB藥物治療耐多藥結覈病（MDR-TB）臨床無交扠耐藥性，療效顯著，且有較高安全性。
목적：관찰화평개불규낙동류약물결합일、이선항TB약물치료내다약결핵병（ MDR-TB）림상유효성급안전성。방법：장156례MDR-TB환자수궤분위2조，기중관찰조채용6MfxZPtoKmPAS/18MfxZPtoPAS（막서사성＋필진선알＋병류이연알＋잡나매소＋대안기수양산）화료방안；대조조채용6LfxZPtoKmPAS/18LfxZPtoPAS（좌양불사성＋필진선알＋병류이연알＋잡나매소＋대안기수양산）화료방안。료정24개월。결과：2조료정완성후，관찰조79례환자현효62례，총유효솔위96．20％，대조조77례환자현효49례，총유효솔위84．42％，2조림상료효비교차이유현저성（ P＜0．01），이관찰조환자3개월、12개월담균음전솔분별위55．69％，73．42％，24개월료정결속시루계유68례환자담균음전，음전솔위86．08％，균고우대조조，차차이현저유통계학의의（P＜0．05），관찰조불량반응발생솔위16．46％（13/79）；대조조위15．58％（12/77），2조비교차이무통계학의의（P＞0．05）。결론：불규낙동류약물결합일、이선항TB약물치료내다약결핵병（MDR-TB）림상무교차내약성，료효현저，차유교고안전성。
Objective:Observation and evaluation of fluoroquinolones in combination with a one second -line anti-TB drugs to treat multidrug-resistant tuberculosis ( MDR-TB) Clinical efficacy and safety .Methods:156 cases of MDR-TB patients were randomly di-vided into two groups, in which the observation group adopted 6MfxZPtoKmPAS/18MfxZPtoPAS Chemotherapy;Controlgroupdopted6LfxZPtoKmPAS/18LfxZPtoPAS chemotherapy, Treatment for 24 months.Results:Observation group of 79 patients, 62 cases had marked effect, total effective rate was 96.20%, Control group 77 patients in 49 cases had marked effect, total effective rate was 84.42%, Comparison of clinical efficacy difference was significant (P<0.01), Observation group the patients 3 months, 12 months spu-tum negative rate were 55.69%, 73.42%, 24 months of treatment at the end of the cumulative sputum negative rate 68patients, sputum negative rate were 86.08%, Significantly higher than that of the control group , and the difference was statistically significant (P<0.05), Observation group the incidence of adverse reactions was 16.46%(13/79); The control group was 15.58%(12/77), The difference between the two groups was not statistically significant (P>0.05).Conclusion:fluoroquinolones in combination with a one second -line anti-TB drugs to treat multidrug -resistant tuberculosis ( MDR-TB) Clinical No cross resistance in curative effect is distinct , and has higher security .
